發(fā)布時間：2018-06-04 02:31

  本文選題：縱向一體化 + 藥品制造企業(yè)��； 參考：《上海師范大學》2013年碩士論文

【摘要】：自改革開放以來，我國藥品制造業(yè)得到了迅速發(fā)展，許多大型藥品制造企業(yè)面臨規(guī)模擴張，需要選擇未來的發(fā)展模式及戰(zhàn)略。在這種背景下，一些大型企業(yè)著手于收購重組上游企業(yè)或自建原料藥制造企業(yè)，實施縱向一體化戰(zhàn)略，試圖解決契約不完備、信息不對稱等問題，達到技術(shù)人才資源共享。但是，縱向一體化一方面可以提高企業(yè)的壟斷勢力，降低交易成本，另一方面卻會因為規(guī)模變大而增加管理成本。對于藥品制造企業(yè)而言，縱向一體化是否能提高企業(yè)的績效？政府是否應該鼓勵藥品制造業(yè)向其他產(chǎn)業(yè)鏈延伸？所以，研究縱向一體化問題能為政府制定藥品制造業(yè)整合政策提供理論支持，為藥品制造業(yè)規(guī)模擴張及未來的發(fā)展模式選擇提供建議。 本文首先系統(tǒng)綜述了國內(nèi)外縱向一體化的理論和研究成果，之后分析了我國藥品制造業(yè)縱向一體化的現(xiàn)狀，揭示出我國藥品制造業(yè)呈現(xiàn)一體化規(guī)模擴大、整合原料藥企業(yè)及外包業(yè)務回歸一體化經(jīng)營的趨勢。而對縱向一體化對于藥品制造企業(yè)績效的影響分析看，縱向一體化能為藥品制造企業(yè)穩(wěn)定上游產(chǎn)品的供給，能提高藥品制造企業(yè)的市場壟斷力，同時能降低藥品制造企業(yè)的交易成本。在實證研究方面，本文運用藥品制造企業(yè)2001年-2010年的數(shù)據(jù)測量了其縱向一體化程度，并將我國藥品制造企業(yè)的縱向一體化指數(shù)與其績效進行檢驗，得出了兩者呈現(xiàn)正相關(guān)關(guān)系的結(jié)論。 國內(nèi)外尚未有對藥品制造企業(yè)的縱向一體化程度與其績效之間的關(guān)系做過系統(tǒng)性的研究。本文將運用經(jīng)濟學相關(guān)理論與已有模型，結(jié)合我國藥品制造企業(yè)的縱向一體化發(fā)展情況，，采用I/O模型中的Davies-Morris指數(shù)法測量藥品制造企業(yè)的一體化程度，并運用SPSS軟件對影響其績效的幾個因素進行回歸分析。 本文通過分析得出了我國藥品制造企業(yè)通過縱向一體化能夠?qū)⑼獠啃詥栴}轉(zhuǎn)為內(nèi)部性問題，提高其市場集中度，降低藥品制造企業(yè)的市場交易成本，避免契約不完備、策略選擇風險以及套牢等帶來的風險，給藥品制造業(yè)帶來規(guī)模正效益。隨著藥品制造企業(yè)縱向一體化程度的增加，藥品制造企業(yè)的績效也在提高，兩者呈現(xiàn)正相關(guān)關(guān)系。政府應該鼓勵有能力的藥品制造企業(yè)實施縱向一體化戰(zhàn)略，鼓勵藥品制造業(yè)向上下游產(chǎn)業(yè)鏈延伸，促進藥品制造企業(yè)生產(chǎn)整合。
[Abstract]:Since the reform and opening up, the pharmaceutical manufacturing industry in China has been developing rapidly. Many large pharmaceutical manufacturing enterprises are facing the expansion of scale and need to choose the future development model and strategy. Under this background, some large enterprises begin to acquire and reorganize upstream enterprises or build their own raw drug manufacturing enterprises, implement vertical integration strategy, try to solve the problems of incomplete contracts and asymmetric information, so as to achieve the sharing of technical talent resources. However, on the one hand, vertical integration can increase monopoly power and reduce transaction cost, on the other hand, it will increase management cost because of increasing scale. For pharmaceutical manufacturing enterprises, can vertical integration improve their performance? Should the government encourage the pharmaceutical industry to expand into other industrial chains? Therefore, the study of vertical integration can provide theoretical support for the government to formulate the integrated policy of pharmaceutical manufacturing industry, and provide suggestions for the scale expansion of pharmaceutical manufacturing industry and the choice of future development model. This paper firstly summarizes the theory and research results of vertical integration at home and abroad, then analyzes the present situation of vertical integration of pharmaceutical manufacturing industry in China, and reveals that the scale of integration of pharmaceutical manufacturing industry in China is expanding. Integration of API enterprises and outsourcing business return to the trend of integrated management. From the analysis of the effect of vertical integration on the performance of pharmaceutical manufacturing enterprises, it can be seen that vertical integration can stabilize the supply of upstream products and enhance the market monopoly power of pharmaceutical manufacturing enterprises. At the same time, it can reduce the transaction cost of pharmaceutical manufacturers. In the aspect of empirical research, this paper uses the data of pharmaceutical manufacturing enterprises from 2001 to 2010 to measure the degree of vertical integration, and tests the vertical integration index and its performance of Chinese pharmaceutical manufacturing enterprises. The conclusion of positive correlation between the two is obtained. No systematic research has been done on the relationship between the degree of vertical integration and the performance of pharmaceutical manufacturing enterprises at home and abroad. In this paper, we will use the relevant theories of economics and existing models, combining with the development of vertical integration of pharmaceutical manufacturing enterprises in China, using the Davies-Morris index method in the I / O model to measure the degree of integration of pharmaceutical manufacturing enterprises. And use SPSS software to influence its performance several factors to carry on the regression analysis. Through the analysis, this paper concludes that the drug manufacturing enterprises in our country can turn the externality into internal problems through vertical integration, improve their market concentration, reduce the market transaction cost of the pharmaceutical manufacturing enterprises, and avoid the incomplete contract. The strategic choice risk and the risk brought about by clamping up will bring the scale positive benefit to the pharmaceutical manufacturing industry. With the increase of the degree of vertical integration of pharmaceutical manufacturing enterprises, the performance of pharmaceutical manufacturing enterprises is also improving, which shows a positive correlation. The government should encourage the competent pharmaceutical manufacturing enterprises to implement vertical integration strategy, encourage the pharmaceutical manufacturing industry to extend to the upstream and downstream industrial chains, and promote the production integration of pharmaceutical manufacturing enterprises.
【學位授予單位】：上海師范大學
【學位級別】：碩士
【學位授予年份】：2013
【分類號】：F272.5;F426.72

【參考文獻】

相關(guān)期刊論文 前10條

1 渠立榕;黃丹;;縱向一體化戰(zhàn)略績效實證研究——以臺灣地區(qū)為例[J];安徽農(nóng)業(yè)科學;2007年31期

2 薛繼亮;李錄堂;;基于投入產(chǎn)出的農(nóng)業(yè)產(chǎn)業(yè)一體化水平研究[J];商業(yè)研究;2011年01期

3 里昕;揭筱紋;;企業(yè)縱向戰(zhàn)略聯(lián)盟組建影響因素分析——基于我國上市公司的實證研究[J];財經(jīng)論叢;2007年02期

4 周勤;縱向一體化趨勢和市場競爭力關(guān)系研究——以江蘇制造業(yè)的實證為例[J];中國工業(yè)經(jīng)濟;2003年07期

5 孟永利,侯鵬偉;加入WTO對中國醫(yī)藥產(chǎn)業(yè)的影響及應對策略[J];哈爾濱商業(yè)大學學報(社會科學版);2002年02期

6 徐小婷;李躍;;我國醫(yī)藥業(yè)縱向一體化原因分析——基于資產(chǎn)專用性及不完全契約理論[J];黑龍江對外經(jīng)貿(mào);2011年05期

7 劉洋;縱向一體化理論述評[J];華南理工大學學報(社會科學版);2002年01期

8 周勤;縱向一體化測度理論評介[J];經(jīng)濟學動態(tài);2002年01期

9 潘愛華;;產(chǎn)業(yè)集群競爭力實證分析——以泰州醫(yī)藥產(chǎn)業(yè)集群為例[J];經(jīng)濟研究導刊;2008年18期

10 熊華平;金維興;;基于縱向一體化的中國建筑企業(yè)發(fā)展戰(zhàn)略[J];建筑經(jīng)濟;2006年10期

相關(guān)博士學位論文 前1條

1 蘭勇;我國鋁工業(yè)縱向一體化的形成及其影響研究[D];中南大學;2010年

相關(guān)碩士學位論文 前6條

1 魏程玲;X公司后向一體化戰(zhàn)略研究[D];廈門大學;2006年

2 鄭子輝;A化工公司后向一體化戰(zhàn)略研究[D];南京理工大學;2007年

3 趙春艷;企業(yè)并購與我國醫(yī)藥產(chǎn)業(yè)結(jié)構(gòu)優(yōu)化研究[D];山東大學;2008年

4 李怡霄;鋼鐵企業(yè)縱向一體化對企業(yè)績效作用機理研究[D];大連理工大學;2009年

5 于洋;中國鋼鐵上市公司縱向整合動因、模式與績效研究[D];復旦大學;2009年

6 陳勝男;中國汽車產(chǎn)業(yè)縱向一體化問題研究[D];山東大學;2010年

本文編號：1975442